Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence

Michelle A. Neben-Wittich, Michael C. Stauder, Fernando Quevedo, Michele M. Corsini, Matthew J. Iott, Robert C. Miller

Research output: Contribution to journalReview article

Abstract

Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5% or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.

Original languageEnglish (US)
JournalEuropean journal of Clinical and Medical Oncology
Volume2
Issue number1
StatePublished - Sep 9 2010

Keywords

  • Adenocarcinoma
  • Adjuvant
  • Chemoradiation
  • Chemotherapy
  • Pancreas
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence'. Together they form a unique fingerprint.

  • Cite this

    Neben-Wittich, M. A., Stauder, M. C., Quevedo, F., Corsini, M. M., Iott, M. J., & Miller, R. C. (2010). Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence. European journal of Clinical and Medical Oncology, 2(1).